Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: A therapeutic strategy for parkinson's disease

Medicine and Dentistry

• Glial Cell Line Derived Neurotrophic Factor 100%
• Macrophage 100%
• Obstetric Delivery 66%
• Brain 66%
• Combination Therapy 33%
• Tyrosine 3 Monooxygenase 33%
• Dopamine Agonist 33%
• Blood Brain Barrier 33%
• Neuroprotective Agent 33%
• Neurodegeneration 33%
• Parkinson's Disease 33%
• Striatum 33%
• 1,2,3,6 Tetrahydro 1 Methyl 4 Phenylpyridine 33%
• Substantia nigra 33%
• Treatment of Parkinson's Disease 33%
• Bone Marrow Stem Cell 33%
• Neuron 33%
• Degeneration 16%
• Transplantation 16%
• Ex Vivo 16%
• Promoter Region 16%
• Nerve Cell Degeneration 16%
• Development 16%
• Neurotoxin 16%
• Lentivirus 16%
• Hypoactivity 16%
• Gene 16%
• Nerve Fiber Regeneration 16%
• Therapeutic Procedure 16%

Neuroscience

• Glial Cell Line-Derived Neurotrophic Factor 100%
• Neuroprotective Agent 33%
• Tyrosine Hydroxylase 33%
• Blood Brain Barrier 33%
• Dopaminergic 33%
• Parkinson's Disease 33%
• Neurodegeneration 33%
• MPTP 33%
• Promoter Region 16%
• Nerve Cell Degeneration 16%
• Neurotoxin 16%
• Hypoactivity 16%
• Nerve Fiber Regeneration 16%
• Gene 16%